Genistein effects on quality of life and depression symptoms in osteopenic postmenopausal women: a 2-year randomized, double-blind, controlled study
Genistein effects on quality of life and depression symptoms in osteopenic postmenopausal women: a 2-year randomized, double-blind, controlled study
复制标题
DOI：
10.1007/s00198-013-2512-5
复制
发表时间：
2014-03-01
影响因子：
4
通讯作者：
Bagnato, G.
中科院分区：
文献类型：
--
作者：
Atteritano, M.;Mazzaferro, S.;Bagnato, G.
绝经后雌激素水平下降与女性的一些年龄相关的生理和心理变化有关，包括生活质量的下降。在绝经后骨质疏松症的妇女中，每天服用54毫克的植物雌激素染料木素2年后意味着生活质量和抑郁症状的改善。绝经后雌激素下降与女性的几个年龄相关的生理和心理变化有关，包括感觉到的生活质量(QOL)的下降。一些激素治疗的试验表明，干预对生活质量参数有有益的影响。然而，由于已知或怀疑常规激素治疗的严重副作用，有必要选择替代疗法。我们进行了一项双盲随机安慰剂对照试验，使用54 mg异黄酮染料木素或安慰剂，为期2年。在这项研究中，我们招募了262名年龄在49岁到67岁的绝经后妇女。在基线、1年后和最后一次访问时，参与者填写了36个问题的简表(SF-36)和Zung自评抑郁量表(ZSDS)。对于安慰剂组，SF-36的所有维度的分数在1年和2年后都有所下降。金雀异黄素组在研究结束时SF-36的所有维度都有增加。然而，两个干预组之间的分数变化有统计学意义上的差异。总而言之，这项随机试验的结果表明，染料木素改善了绝经后骨质疏松症女性的生活质量(健康状况、生活满意度和抑郁)。
Postmenopausal estrogen decline is implicated in several age-related physical and psychological changes in women, including decreases in perceived quality of life. The phytoestrogen genistein at a dose of 54 mg daily in osteopenic postmenopausal women after 2 years implies an improvement on quality of life and depression symptoms.Postmenopausal estrogen decline is implicated in several age-related physical and psychological changes in women, including decreases in perceived quality of life (QoL). A number of trials with hormone therapy showed beneficial effects of the intervention on quality of life parameters. However, because of known or suspected serious side effects of conventional hormone therapy, there is a need for alternatives.We conducted a double-blind randomized placebo-controlled trial using the isoflavone genistein, 54 mg, or placebo for 2 years. In this trial, we recruited 262 postmenopausal women aged 49 to 67 years.At baseline, after 1 year, and at final visit, participants filled in the Short Form of 36 questions (SF-36) and the Zung Self-rating Depression Scale (ZSDS). For the placebo group, scores on all dimensions of the SF-36 decreased after 1 and 2 years. The genistein group showed increases on all dimensions of the SF-36 at the end of the study. There were, however, statistically significant differences in changes of scores between the two intervention groups. For the ZSDS, similarly, significant differences were found between groups.In conclusion, the findings of this randomized trial showed that genistein improves quality of life (health status, life satisfaction, and depression) in osteopenic postmenopausal women.